Literature DB >> 20224322

Contemporary indications and therapeutic implications for digoxin use.

Mayank K Mittal1, Priya Chockalingam, Anand Chockalingam.   

Abstract

Heart failure (HF) is a leading cause of morbidity and mortality. Appropriate medical therapy using angiotensin converting enzyme inhibitors and beta-blockers improves outcomes in HF, whereas the role of digoxin is still not clearly defined. Digoxin is currently recommended for patients with HF who are symptomatic despite standard therapy and for controlling the ventricular rate in atrial fibrillation. Digoxin is a time-tested drug that accounts for 20 million drug prescriptions annually in the United States. It has favorable hemodynamic effects for patients with HF and atrial tachyarrhythmias. We conducted a systematic literature search for the current indications for digoxin. Despite extensive research and safety data, the literature suggests that digoxin is underused in clinical settings. Citing the literature where available, our review highlights the various clinical settings where digoxin is indicated. Despite difficulties with designing prospective studies in acute HF settings and lack of outcomes data, we believe that digoxin will continue to serve an important role in optimizing care in certain acute and chronic cardiac conditions.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20224322     DOI: 10.1097/MJT.0b013e3181c6c0d2

Source DB:  PubMed          Journal:  Am J Ther        ISSN: 1075-2765            Impact factor:   2.688


  2 in total

1.  Darexaban (YM150), an oral direct factor Xa inhibitor, has no effect on the pharmacokinetics of digoxin.

Authors:  Takeshi Kadokura; Dorien Groenendaal; Marten Heeringa; Roelof Mol; Frank Verheggen; Alberto Garcia-Hernandez; Hartmut Onkels
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2013-06-11       Impact factor: 2.441

2.  Ryanodine receptor phosphorylation by oxidized CaMKII contributes to the cardiotoxic effects of cardiac glycosides.

Authors:  Hsiang-Ting Ho; Bin Liu; Jedidiah S Snyder; Qing Lou; Elizabeth A Brundage; Florencia Velez-Cortes; Honglan Wang; Mark T Ziolo; Mark E Anderson; Chandan K Sen; Xander H T Wehrens; Vadim V Fedorov; Brandon J Biesiadecki; Thomas J Hund; Sándor Györke
Journal:  Cardiovasc Res       Date:  2013-10-08       Impact factor: 10.787

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.